News
LIVN
78.18
0.00%
0.00
LivaNova (LIVN) Could Be 12% Undervalued Following Recent Share Price Cooling
Simply Wall St · 2d ago
LivaNova Director Sells 1,650 Shares for $131,500
The Motley Fool · 2d ago
Weekly Report: what happened at LIVN last week (0831-0904)?
Weekly Report · 6d ago
Insider Shake-Up: High-Level LivaNova Stock Sale Turns Heads
TipRanks · 09/03 02:05
Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90
Benzinga · 09/02 16:33
LivaNova price target raised to $90 from $87 at Piper Sandler
TipRanks · 09/02 10:45
LivaNova (LIVN) Stock May Be Below Fair Value But Fair On Earnings
Simply Wall St · 09/01 10:30
Weekly Report: what happened at LIVN last week (0824-0828)?
Weekly Report · 08/31 09:09
LivaNova: Careful About The Valuation And Upside
Seeking Alpha · 08/25 14:34
Artisan International Small-Mid Fund Q2 2026 Portfolio Review
Seeking Alpha · 08/24 19:03
Is LivaNova (LIVN) Fairly Valued As Growth Hopes Meet Reimbursement Risks?
Simply Wall St · 08/24 14:24
Weekly Report: what happened at LIVN last week (0817-0821)?
Weekly Report · 08/24 09:10
LivaNova selloff brings attractive entry point, says Mizuho
TipRanks · 08/21 11:20
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NASDAQ · 08/17 17:17
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NASDAQ · 08/17 17:06
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NASDAQ · 08/17 16:59
Weekly Report: what happened at LIVN last week (0810-0814)?
Weekly Report · 08/17 09:10
LivaNova (LIVN), What Is Behind The Fresh Attention?
Simply Wall St · 08/16 22:24
Top LivaNova Executive Makes Notable Move With Insider Stock Sale
TipRanks · 08/14 02:06
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
Simply Wall St · 08/10 17:26
More
Webull provides a variety of real-time LIVN stock news. You can receive the latest news about Livanova Plc through multiple platforms. This information may help you make smarter investment decisions.
About LIVN
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.